Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losmapimod Phase 2 study in facioscapulohumeral muscular dystrophy
2019-001181-15Phase 2Active
- Sponsor
- Fulcrum Therapeutics
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in facioscapulohumeral muscular dystrophy (FSHD) comparing Losmapimod with Placebo (2 arms). Primary endpoint: Change from baseline in DUX4 activity in affected skeletal muscle at 16 weeks. Started May 2019; status: active.
02
Drugs
losmapimod
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on 2019-001181-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001181-15.